<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216483">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266877</url>
  </required_header>
  <id_info>
    <org_study_id>3144A1-200</org_study_id>
    <secondary_id>B1891037</secondary_id>
    <nct_id>NCT00266877</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puma Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puma Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether HKI-272 is safe and effective in treating
      non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate for neratinib in patients with non-small cell lung cancer</measure>
    <time_frame>At screening, after 1 month of treatment, and then every 2 months throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>At screening, weekly for the first month, then at weeks 1 and 4 thereafter, and at the final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on quality of life based on results from quality-of-life questionnaires (FACT-L and EQ-5D)</measure>
    <time_frame>At screening, on day 1 of months 3 and 5, and at the end of treamtent visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of neratinib</measure>
    <time_frame>Prior to the first dose and on day 1 of months 2 through 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate for neratinib in patients with non-small cell lung cancer</measure>
    <time_frame>At screening, after 1 month of treatment, and then every 2 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response for neratinib in patients with non-small cell lung cancer</measure>
    <time_frame>At screening, after 1 month of treatment, and then every 2 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival for neratinib in patients with non-small cell lung cancer</measure>
    <time_frame>At screening, after 1 month of treatment, and then every 2 months throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose disease has progressed following &gt; or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose disease has progressed following &gt; or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, &lt; or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Neratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Neratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKI-272</intervention_name>
    <description>320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Neratinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of NSCLC and current stage IIIB (with pleural effusion) or IV,
             not curable with conventional therapy. For Arm C, less than or equal to 20 pack-years
             smoking history and current non smoker. A pack year = number of packs of cigarettes
             smoked per day x years smoked.

          -  Progression following at least 12 weeks of treatment with Tarceva or Iressa. (Arms A
             and B only)

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2 (not
             declining within past 2 weeks).

          -  Tumor sample available and adequate for analysis.

          -  At least one measurable target lesion.

          -  Adequate cardiac, kidney, and liver function

          -  Adequate blood counts

        Exclusion Criteria:

          -  More than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic
             disease.

          -  Significant cardiac disease or dysfunction.

          -  Prior treatment with anthracyclines with cumulative dose of &gt;400 mg/m^2.

          -  Active central nervous system metastases, as indicated by clinical symptoms and/or
             progressive growth.

          -  Use of Tarceva or Iressa within 14 days of treatment day 1 (Arms A and B only).

          -  Major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer
             therapy within 3 weeks of treatment day 1.

          -  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a
             major symptom.

          -  Inability or unwillingness to swallow HKI-272 capsules.

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Puma</last_name>
    <role>Study Director</role>
    <affiliation>Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-7284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-122</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 10, 2012</lastchanged_date>
  <firstreceived_date>December 16, 2005</firstreceived_date>
  <firstreceived_results_disposition_date>February 26, 2009</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
